Hyperparasitaemia and low dosing are an important source of anti-malarial drug resistance

Malaria Journal

Volumn 8, Issue 1, 2009, Pages

  White, Nicholas J ^a,b   Pongtavornpinyo, Wirichada ^a   Maude, Richard J ^a,b   Saralamba, Sompob ^a   Aguas, Ricardo ^c   Stepniewska, Kasia ^a,b   Lee, Sue J ^a,b   Dondorp, Arjen M ^a,b   White, Lisa J ^a   Day, Nicholas Pj ^a,b  

^a MAHIDOL UNIVERSITY   (Thailand)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c INSTITUTO GULBENKIAN DE CIÊNCIA   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; ARTEMETHER; ARTEMETHER PLUS BENFLUMETOL; ARTEMISININ; ARTEMISININ DERIVATIVE; ARTESUNATE; ATOVAQUONE; ATOVAQUONE PLUS PROGUANIL; CHLOROQUINE; DIHYDROARTEMISININ PLUS PIPERAQUINE; DIHYDROFOLATE REDUCTASE; FANSIDAR; MEFLOQUINE; PYRIMETHAMINE;

ANTIMALARIAL DRUG RESISTANCE; ANTIMALARIAL DRUG SUSCEPTIBILITY; ARTICLE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG EXPOSURE; DRUG HALF LIFE; DRUG MECHANISM; GENE MUTATION; HOST PARASITE INTERACTION; HOST RESISTANCE; HUMAN; HYPERPARASITEMIA; IMMUNE RESPONSE; INFECTION CONTROL; INFECTION RISK; LOW DRUG DOSE; MALARIA; MALARIA FALCIPARUM; MOSQUITO; NONHUMAN; PARASITE SURVIVAL; PARASITE TRANSMISSION; PARASITEMIA; PATIENT COMPLIANCE; PLASMODIUM FALCIPARUM; RECURRENCE RISK; SINGLE DRUG DOSE; SPOROZOITE; TREATMENT FAILURE; TREATMENT OUTCOME; BLOOD; DISEASE TRANSMISSION; DRUG EFFECT; DRUG RESISTANCE; PARASITOLOGY; PLASMODIUM; RECURRENT DISEASE;

ANTIMALARIALS; ARTEMISININS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE; HUMANS; MALARIA; PARASITEMIA; PLASMODIUM; RECURRENCE;

EID: 72349090161     PISSN: None     EISSN: 14752875     Source Type: Journal    
DOI: 10.1186/1475-2875-8-253     Document Type: Article

References (47)

1. Chemotherapy and drug resistance in malaria. W Peters, Academic press, London 2 1987
2. The prevention of antimalarial drug resistance. W Peters, Pharmacol Ther 1990 47 499 508 2290858
3. The de novo selection of drug-resistant malaria parasites. NJ White W Pongtavornpinyo, Proc R Soc Lond B Biol Sci 2003 270 545 554
4. Antimalarial drug resistance. NJ White, J Clin Invest 2004 113 1084 1092 15085184
5. Population biology and antimalarial resistance: The transmission of antimalarial drug resistance in Plasmodium falciparum. KI Barnes NJ White, Acta Trop 2005 94 230 224 15878154
6. Probability of emergence of antimalarial resistance in different stages of the parasite life cycle. W Pongtavornpinyo IM Hastings A Dondorp LJ White RJ Maude S Saralamba NP Day NJ White MF Boni, Evolutionary Applications 2009 2 1 52 61
7. The emergence of drug-resistant malaria. IM Hastings MJ Mackinnon, Parasitology 1998 117 411 7 9836305
8. Intercontinental spread of pyrimethamine-resistant malaria. C Roper R Pearce S Nair B Sharp F Nosten T Anderson, Science 2004 305 1124 15326348
9. A retrospective examination of sporozoite- and trophozoite-induced infections with Plasmodium falciparum: development of parasitologic and clinical immunity during primary infection. WE Collins GM Jeffery, Am J Trop Med Hyg 1999 61 Suppl 4 19
10. Population dynamics of the Plasmodium falciparum parasite within the adult human host in the absence of antimalarial drugs. JA Simpson L Aarons WE Collins G Jeffery NJ White, Parasitology 2002 124 247 263 11922427
11. Mathematical model ofthe first wave of Plasmodium falciparum asexual parasitemia in non-immune and vaccinated individuals. K Dietz G Raddatz L Molineaux, Am J Trop Med Hyg 2006 75 2 Suppl 46 55 16931815
12. Some enumerative studies on malaria fever. R Ross D Thompson, Ann Trop Med Parasitol 1910 4 267 313
13. Symptomatology: general considerations and falciparum malaria. SF Kitchen, Malariology Philadelphia: W B Saunders, Boyd MF, 1949 2 996 1017
14. Sidelights on malaria in man obtained by subinoculation experiments. NH Fairley, Trans R Soc Trop Med Hyg 1947 40 521 676
15. Estimation of the total parasite biomass in acute falciparum malaria from plasma PfHRP2. AM Dondorp V Desakorn W Pongtavornpinyo D Sahassananda K Silamut K Chotivanich PN Newton P Pitisuttithum AM Smithyman NJ White NPJ Day, PLoS Medicine 2005 2 204 16104831
16. Assessment of the pharmacodynamic properties of antimalarial drugs in-vivo. NJ White, Antimicrob Agents Chemother 1997 41 1413 1422 9210658
17. Infectivity to mosquitoes of Plasmodium falciparum as related to gametocyte density and duration of infection. GM Jeffery DE Eyles, Am J Trop Med Hyg 1955 4 781 789 13259002
18. Pharmacokinetic determinants of the window of selection for antimalarial drug resistance. K Stepniewska NJ White, Antimicrob Agents Chemother 2008 52 1589 1596 18299409
19. Risk factors for gametocyte carriage in uncomplicated falciparum malaria. RN Price F Nosten C Luxemburger L Phaipun F ter Kuile M van Vugt T Chongsuphajaisiddhi NJ White, Am J Trop Med Hyg 1999 60 1019 1023 10403336
20. The development of pyrimethamine resistance by Plasmodium falciparum. RW Burgess MD Young, Bull WHO 1959 20 37 46 13638788
21. The effect of parasite populations on the curative action of pyrimethamine. DC Martin JD Arnold, Trans R Soc Trop Med Hyg 1968 62 379 384 4872957
22. Clinical studies of atovaquone, alone or in combination with other antimalarial drugs, for treatment of acute uncomplicated malaria in Thailand. S Looareesuwan C Viravan HK Webster DE Kyle DB Hutchinson CJ Canfield, Am J Trop Med Hyg 1996 54 62 66 8651372
23. Plasmodium falciparum Pfmdr1 amplification, mefloquine resistance, and parasite fitness. P Preechapornkul M Imwong K Chotivanich W Pongtavornpinyo AM Dondorp NPJ Day NJ White S Pukrittayakamee, Antimicrob Agents Chemother 2009 53 1509 15 19164150
24. Intrahost selection of Plasmodium falciparum Pfmdr1 alleles after antimalarial treatment on the northwestern border of Thailand. AC Uhlemann R McGready EA Ashley A Brockman P Singhasivanon S Krishna NJ White F Nosten R Price, J Infect Dis 2007 195 134 41 17152017
25. Spread of anti-malarial drug resistance: mathematical model with implications for ACT drug policies. W Pongtavornpinyo S Yeung IM Hastings AM Dondorp NP Day NJ White, Malar J 2008 7 229 18976503
26. Novel point mutations in thedihydrofolate reductase gene of Plasmodium vivax: evidence for sequential selection by drug pressure. M Imwong S Pukrittakayamee S Looareesuwan G Pasvol J Poirriez NJ White G Snounou, Antimicrob Agents Chemother 2003 47 1514 1521 12709316
27. Predictors of mefloquine treatment failure: a prospective study in 1590 patients with uncomplicated falciparum malaria. FO ter Kuile C Luxemburger F Nosten L Phaipun T Chongsuphajaisiddhi NJ White, Trans R Soc Trop Med Hyg 1995 89 660 664 8594690 (Pubitemid 26016357)
28. Risk factors of chloroquine resistance in Plasmodium falciparum malaria. FI Hess A Iannuzzi J Leafasia D Cowdrey HD Nothdurft F VonSonnenburg T Löscher KH Rieckmann, Acta Trop 1996 61 293 306 8910654
29. Age, temperature, and parasitaemia predict chloroquine treatment failure and anaemia in children with uncomplicated Plasmodium falciparum malaria. DH Hamer WB MacLeod E Addo-Yobo CP Duggan B Estrella WW Fawzi JK Konde-Lule V Mwanakasale ZG Premji F Sempértegui FP Ssengooba K Yeboah-Antwi JL Simon, Trans R Soc Trop Med Hyg 2003 97 422 8 15259472
30. The impact of age, temperature, and parasite density on treatment outcomes from antimalarial clinical trials in Kampala, Uganda. G Dorsey AF Gasasira R Machekano MR Kamya SG Staedke A Hubbard, Am J Trop Med Hyg 2004 71 531 6 15569778
31. Predictors of antimalarial treatment failure in an area of unstable malaria transmission in eastern Sudan. I Adam KA Elmardi EM Malik, Trans R Soc Trop Med Hyg 2009 103 21 4 18718621
32. Deployment of early diagnosis and mefloquine- artesunate treatment of falciparum malaria in Thailand: the Tak Malaria Initiative. VI Carrara S Sirilak J Thonglairuam C Rojanawatsirivet S Proux V Gilbos A Brockman EA Ashley R McGready S Krudsood S Leemingsawat S Looareesuwan P Singhasivanon NJ White F Nosten, PLoS Med 2006 3 18 16354108
33. Genetic diversity and dynamicsof Plasmodium falciparum and P. vivax populationsin multiply infected children with asymptomatic malaria infections in Papua New Guinea. MC Bruce MR Galinski JW Barnwell CA Donnelly M Walmsley MP Alpers D Walliker KP Day, Parasitology 2000 121 257 72 11085246
34. Treatment of Plasmodiumfalciparum malaria with pyrimethamine-sulfadoxine: selective pressure for resistance is a function of long elimination half-life. WM Watkins M Mosobo, Trans R Soc Trop Med Hyg 1993 87 75 8 8465404
35. Mutant selection window hypothesis updated. K Drlica X Zhao, Clin Infect Dis 2007 44 81 8
36. Mefloquine pharmacokinetic-pharmacodynamic models: implications for dosing and resistance. JA Simpson ER Watkins RN Price L Aarons DE Kyle NJ White, Antimicrob Agents Chemother 2000 44 3414 3424 11083649
37. Blood examination and prognosis in acute falciparum malaria. JW Field, Trans R Soc Trop Med Hyg 1949 43 33 68 18139104
38. Pre-referral rectal artesunate to prevent death and disability in severe malaria: a placebo-controlled trial. M Gomes M Faiz J Gyapong M Warsame T Agbenyega A Babiker F Baiden E Yunus F Binka C Clerk P Folb R Hassan M Hossain O Kimbute A Kitua S Krishna C Makasi N Mensah Z Mrango P Olliaro R Peto T Peto M Rahman I Ribeiro R Samad NJ White the Study 13 Research Group, Lancet 2009 373 557 66 19059639
39. Daraprim resistance in experimental malarial infections. IM Rollo, Nature 1952 170 415 12993182
40. Drug resistance in malaria parasites of animals and man. W Peters, Adv Parasitol 1998 41 1 62 9734291
41. The effect of combinations of qinghaosu (artemisinin) with standard antimalarial drugs in the suppressive treatment of malaria in mice. AN Chawira DC Warhurst BL Robinson W Peters, Trans R Soc Trop Med Hyg 1987 81 554 558 3328341
42. Antimalarial drug resistance and combination chemotherapy. NJ White, Phil Trans R Soc Lond B 1999 354 739 749
43. Intensity of malaria transmission and the evolution of drug resistance. IM Hastings WM Watkins, Acta Trop 2005 94 218 229 15847846
44. Tolerance is the key to understanding antimalarial drug resistance. IM Hastings WM Watkins, Trends Parasitol 2006 22 71 7 16406706
45. Intercontinental spread of pyrimethamine-resistant malaria. C Roper R Pearce S Nair B Sharp F Nosten T Anderson, Science 2004 305 1124 15326348
46. Antimalarial dosing regimens and drug resistance. KI Barnes WM Watkins NJ White, Trends Parasitol 2008 24 127 34 18262470
47. Sulfadoxine-pyrimethamine pharmacokinetics in malaria: pediatric dosing implications. KI Barnes F Little PJ Smith A Evans WM Watkins NJ White, Clin Pharmacol Ther 2006 80 582 96 17178260